Alvotech and Advanz Pharma Submit Proposed Eylea 8 mg Biosimilar to EMA
AVT29 was submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli (aflibercept 2 mg).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.